Лечение эпилепсии мезенхимальными стволовыми клетками: обзор литературы

В последние несколько лет результаты экспериментальных и клинических исследований показали, что воспаление может быть как следствием, так и причиной эпилепсии. Отличительными особенностями мезенхимальных стволовых клеток (МСК) являются их иммуномодулирующие и противовоспалительные свойства, что свидетельствует о перспективах использования МСК в области лечения эпилепсии.

В статье представлен обзор литературы по доклиническому и клиническому применению МСК в лечении эпилепсии, изложен механизм лечебного действия МСК при данном заболевании. Авторы сделали акцент на анализе всех имеющихся в литературе клинических случаев применения МСК в лечении эпилепсии, а также на эффективности и нежелательных эффектах проведенной терапии. Использование МСК действительно обладает значительным эффектом в уменьшении количества приступов, положительно влияет на психические функции, однако в настоящее время данный метод терапии недостаточно готов к широкому клиническому применению в связи с коротким периодом наблюдения за пациентами в проведенных клинических испытаниях и повышенными рисками развития иммунологических и онкологических осложнений у пациентов.

1. Abdanipour A., Tiraihi T., Mirnajafi-Zadeh J. Improvement of the pilocarpine epilepsy model in rat using bone marrow stromal cell. Neurol Res 2011;33(6):625–32. DOI: 10.1179/1743132810Y.0000000018

2. Agadi S., Shetty A.K. Concise review: prospects of bone marrow mononuclear cells and mesenchymal stem cells for treating status epilepticus and chronic epilepsy. Stem Cells 2015;33(7):2093–103. DOI: 10.1002/stem.2029

3. Berebichez-Fridman R., Montero-Olvera P.R. Sources and clinical applications of mesenchymal stem cells: state-of-the-art review. Sultan Qaboos Univ Med J 2018;18(3):e264–e277. DOI: 10.18295/squmj.2018.18.03.002

4. Corcione A., Benvenuto F., Ferretti E. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107(1):367–72. DOI: 10.1182/blood-2005-07-2657

5. Cui L., Kerkelä E., Bakreen A. et al. The cerebral embolism evoked by intra-areterial delivery of allogenic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cell Res Ther 2015;6(1):11. DOI: 10.1186/scrt544

6. Cunningham J.J., Ulbright T.M., Pera M.F. et al. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 2012;30(9):849–57. DOI: 10.1038/nbt.2329

7. DaCosta J.C., Portuguez M.W., Marinowic D.R. et al. Safety and seizure control in patients with mesial temporal lobe epilepsy treated with regional superselective intra-arterial injection of autologous bone marrow mononuclear cells. J Tissue Eng Regen Med 2018;12(2):e648–e656. DOI: 10.1002/term.2334

8. Dong H., Li G., Shang C. et al. Umbilical cord mesenchymal stem cell (UC-MSCs) transplantations for cerebral palsy. Am J Transl Res 2018;10(3):901–6.

9. Fischer U.M., Harting M.T., Jimenez F. et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009;18(5):683–92. DOI: 10.1089/scd.2008.0253

10. Fukumura S., Sasaki M., Kataoka-Sasaki Y. et al. Intravenous infusion of mesenchymal stem cells reduces epileptogenesis in a rat model of status epilepticus. Epilepsy Res 2018;141:56–63. DOI: 10.1016/j.eplepsyres.2018.02.008

11. Hlebokazov F., Dakukina T., Ihnatsenko S. et al. Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study. Adv Med Sci 2017;62(2):273–9. DOI: 10.1016/j.advms.2016.12.004

12. Hlebokazov F., Dakukina T., Potapnev M. et al. Clinical benefits of single vs repeated courses of mesenchymal stem cell therapy in epilepsy patients. Clin Neurol Neurosurg 2021;207:106736. DOI: 10.1016/j.clineuro.2021.106736

13. Huang P.Y., Shih Y.H., Tseng Y.J. et al. Xenograft of human umbilical mesenchymal stem cells from Wharton’s jelly as a potential therapy for rat pilocarpine-induced epilepsy. Brain Behav Immun 2016;54:45–58. DOI: 10.1016/j.bbi.2015.12.021

14. Huicong K., Zheng X., Furong W. et al. The imbalanced expression of adenosine receptors in an epilepsy model corrected using targeted mesenchymal stem cell transplantation. Mol Neurobiol 2013;48(3):921–30. DOI: 10.1007/s12035-013-8480-0

15. Jiang W., Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif 2020;53(1):e12712. DOI: 10.1111/cpr.12712

16. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439–41. DOI: 10.1016/S0140-6736(04)16104-7

17. Li P., Gong Z., Shultz L.D. et al. Mesenchymal stem cells: From regeneration to cancer. Pharmacol Ther 2019;200:42–54. DOI: 10.1016/j.pharmthera.2019.04.005

18. Liu J., Liu Q., Chen X. The immunomodulatory effects of mesenchymal stem cells on regulatory B сells. Front Immunol 2020;14(11): 1843. DOI: 10.3389/fimmu.2020.01843

19. Long Q., Upadhya D., Hattiangady B. et al. Intranasal MSCs-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci USA 2017;114(17):E3536–E3545. DOI: 10.1073/pnas.1703920114

20. Melief S.M., Schrama E., Brugman M.H. et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013;31(9):1980–91. DOI: 10.1002/stem.1432

21. Milczarek O., Jarocha D., Starowicz-Filip A. et al. Multiple autologous bone marrow-derived CD271(+) mesenchymal stem cell transplantation overcomes drug-resistant epilepsy in children. Stem Cells Transl Med 2018;7(1):20–33. DOI: 10.1002/sctm.17-0041

22. Perucca P., Scheffer I.E., Kiley M. The management of epilepsy in children and adults. Med J Aust 2018;208(5):226–33. DOI: 10.5694/mja17.00951

23. Pitkänen A., Lukasiuk K., Dudek F.E. et al. Epileptogenesis. Cold Spring Harb Perspect Med 2015;5(10):a022822. DOI: 10.1101/cshperspect.a022822

24. Pittenger M.F., Discher D.E., Péault B.M. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 2019;4:22. DOI: 10.1038/s41536-019-0083-6

25. Rana A., Musto A.E. The role of inflammation in the development of epilepsy. J Neuroinflamm 2018;15(1):144. DOI: 10.1186/s12974-018-1192-7

26. Rani S., Ryan A.E., Griffin M.D. et al. Mesenchymal stem cellderived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther 2015;23(5):812–23. DOI: 10.1038/mt.2015.44

27. Ren G., Zhang L., Zhao X. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2(2):141–50. DOI: 10.1016/j.stem.2007.11.014

28. Rodríguez-Fuentes D.E., Fernández-Garza L.E., Samia-Meza J.A. et al. Mesenchymal stem cells current clinical applications: a systematic review. Arch Med Res 2021;52(1):93–101. DOI: 10.1016/j.arcmed.2020.08.006

29. Salem N.A., El-Shamarka M., Khadrawy Y. et al. New prospects of mesenchymal stem cells for ameliorating temporal lobe epilepsy. Inflammopharmacology 2018;26(4):963–72. DOI: 10.1007/s10787-018-0456-2

30. Shaimardanova A.A, Chulpanova D.S., Mullagulova A.I. et al. Gene and cell therapy for epilepsy: a mini review. Front Mol Neurosci 2022 11;15:868531. DOI: 10.3389/fnmol.2022.868531

31. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 2012;136(2):133–8. DOI: 10.1111/j.1365-2567.2012.03567.x

32. Shi Y., Su J., Roberts A.I. et al. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012;33(3):136–43. DOI: 10.1016/j.it.2011.11.004

33. Shorvon S. The concept of symptomatic epilepsy and the complexities of assigning cause in epilepsy. Epilepsy Behav 2014;32:1–8. DOI: 10.1016/j.yebeh.2013.12.025

34. Sole A., Grossetête S., Heintzé M. et al. Unraveling ewing sarcoma tumorigenesis originating from patient-derived mesenchymal stem cells. Cancer Res 2021;81(19):4994–5006. DOI: 10.1158/0008-5472.CAN-20-3837

35. Szczepanik E., Mierzewska H., Antczak-Marach D. et al. Intrathecal infusion of autologous adipose-derived regenerative cells in autoimmune refractory epilepsy: evaluation of safety and efficacy. Stem Cells Int 2020;2020:7104243. DOI: 10.1155/2020/7104243

36. Tropel P., Platet N., Platel J. C. et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006;24(12):2868–76. DOI: 10.1634/stemcells.2005-0636

37. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8(9):726–36. DOI: 10.1038/nri2395

38. Venturin G. T., Greggio S., Marinowic D.R. et al. Bone marrow mononuclear cells reduce seizure frequency and improve cognitive outcome in chronic epileptic rats. Life Sci 2011;89(7–8):229–34. DOI: 10.1016/j.lfs.2011.06.006

39. Voulgari-Kokota A., Fairless R., Karamita M. et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp Neurol 2012;236(1):161–70. DOI: 10.1016/j.expneurol.2012.04.011

40. Wang L., Zhao Y., Pan X. et al. Adipose-derived stem cell transplantation improves learning and memory via releasing neurotrophins in rat model of temporal lobe epilepsy. Brain Res 2021;1750:147121. DOI: 10.1016/j.brainres.2020.147121

41. Yagi H., Soto-Gutierrez A., Parekkadan B. et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010;19(6):667–79. DOI: 10.3727/096368910X508762